All posts by imreal

Optimization of Tau PET Imaging for Alzheimer’s Clinical Development, Upcoming Webinar Hosted by Xtalks


Xtalks Life Science Webinars

It will be important to review the current data to understand what we know about Tau in AD and how second-generation tracers are being applied in clinical studies.

Join Victor L. Villemagne, Associate Professor, Department of Molecular Imaging and Therapy, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne and Richard Manber, Biomarker Scientist, IXICO in a live webinar on Friday, April 24, 2020 at 10am EDT (3pm BST/UK).

In recent years, there has been an increasing focus on investigating the role of Tau in the onset and progression of Alzheimer’s Disease (AD), and in other neurodegenerative diseases associated with the accumulation of pathological misfolded Tau, such as progressive supranuclear palsy (PSP) and frontotemporal lobar degeneration (FTLD). Studies using recently introduced second-generation Tau tracers suggests that these tracers are binding to Tau with higher specificity compared to previous tracers, leading to increased interest in Tau within clinical studies. However, it’s still unclear what role Tau imaging will play in clinical trials: should Tau be used as a clinical endpoint; and how does it link to other biomarkers such as amyloid-beta, with some studies suggesting that amyloid-beta triggers the spread of Tau beyond the MTL region.

Given that the majority of Tau studies have been conducted using first-generation PET tracers, which had shown high incidences of off-site binding, it will be important to review the current data to understand what we know about Tau in AD and how second-generation tracers are being applied in clinical studies. Additionally, this webinar will cover the steps being taken to advance Tau PET operational and analytical methodologies in AD clinical studies and other Tau-related neurodegenerative diseases.

For more information or to register for this event, visit Optimization of Tau PET Imaging for Alzheimer’s Clinical Development.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

New UK Study Builds on Growing Body of Evidence for Mood-Boosting Effects of Wild Blueberries on Children and Young Adults (Source: WBANA)


Until more is known about the impact of food on mental health, parents can feel good about helping their children establish healthy eating habits to support cognitive development and wellbeing throughout life, such as eating plenty of colorful plant-based foods, like Wild Blueberries, each day.

A new study, published in the British Journal of Nutrition, adds to the growing body of research linking consumption of wild blueberries to benefits in the mood of adolescents. The study, led by Professor Claire Williams from the School of Psychology & Clinical Language Sciences at the University of Reading, UK, builds upon the group’s earlier research on wild blueberry’s beneficial effects on mood and depression in children and young adults. The team’s findings add to an emerging area in nutrition and psychology research, examining the potential for some foods and dietary components to have a positive impact on mood and a reduction of depression symptoms. The interaction between diet and mood is a new and exciting area of science which has not yet been widely explored.

“This is an exciting finding that underscores the potential for wild blueberries to make a difference to people with depression,” said Claire Williams, Professor of Neuroscience, University of Reading. “Here we showed that four weeks of a daily wild blueberry intervention reduced depression symptoms in a community of adolescents. More extensive studies are clearly required to replicate and extend these findings, not only in healthy participants, but also in clinically referred samples, to assess the potential for use of deeply colored berries as a practical and cost-effective intervention.”

Study Overview

The study, entitled “Effect of 4 weeks daily wild blueberry supplementation on symptoms

of depression in adolescents” furthers Williams’ research to address a major social problem: depression in young adults. It is well known that older children and teenagers undergo a vulnerable period in their cognitive and emotional development, which requires special attention and would benefit from additional research.

The study tested the hypothesis that there is an association between the intake of anthocyanin-rich wild blueberries and mood. In this study, children between the ages of 11 and 17 were split into two groups; one group consumed wild blueberries and the other group consumed a placebo. After four weeks of daily consumption the researchers administered rigorous questionnaires where the young participants provided a self-assessment of certain mood parameters.

Based on the self-report questionnaires, the young study participants who consumed wild blueberries documented a beneficial effect on their mood and reported less depression symptoms, compared to the placebo group. The results also showed, that children and teenagers do not consume the recommended daily amount of fruits and vegetables.

These findings were broadly consistent with other research, including that of the Williams’ team, showing that consuming whole, healthy foods (like wild blueberries) can benefit the brain and behavior. The findings also support evidence obtained from population studies where greater consumption of fruit and vegetables is associated with a lower risk of depression. Overall, this study accompanies 20 years of research, which connects better overall health with the consumption of wild blueberries.

Anthocyanins and Other Flavonoids Affect Cognitive Function

Anthocyanins and other food flavonoids are being investigated for their various health benefits. Anthocyanin flavonoids are the pigments responsible for the purple, blue, red hues of some berries. Anthocyanins are extremely abundant in wild blueberries which is easily seen by the berry’s deep pigmentation. Anthocyanins have antioxidant and anti-inflammatory properties, as well as other health effects which have been demonstrated using several experimental approaches. Results suggest that, in the brain, anthocyanins provide benefits by:


  • Improving cerebral blood flow
  • Regulating glucose delivery to the brain
  • Reducing inflammation and oxidative stress to brain neurons
  • Improving the function of neurons in transmitting signals in the brain

Comments from the Wild Blueberry Association of North America (WBANA)

“Although food and mood research is still an emerging area of study, each bit of research that comes out gets us a little further and guides researchers to the next area of study,” said Kitty Broihier, MS, RD, Nutrition Advisor for the Wild Blueberry Association of North America. “The connection between wild blueberries and mood is a novel area of exploration, and Professor Williams’ team’s work on mood and behavior in children and teens is encouraging. Until more is known about the impact of food on mental health, parents can feel good about helping their children establish healthy eating habits to support cognitive development and wellbeing throughout life, such as eating plenty of colorful plant-based foods, like Wild Blueberries, each day.”

With a growing body of research on wild blueberries and cognitive function in young people that has been published by Williams and team, interest in possible links between food and mental health will undoubtedly gain momentum in the science community. Two related studies by Williams and team are referenced in these releases:

  • New Wild Blueberry Study Indicates Potential Mood-Boosting Effect in Young Adults and Children, 2017
  • New Study Suggests Wild Blueberries Boost Memory and Concentration in Elementary School Children, 2015

About WBANA

The Wild Blueberry Association of North America (WBANA) is a trade association of growers and processors of Wild Blueberries from Maine and Canada who are dedicated to bringing the Wild Blueberry health story and unique Wild Advantages to consumers and the trade worldwide. WBANA is dedicated to furthering research that explores the health potential of Wild Blueberries. For twenty years WBANA has hosted the Health Research Summit in Bar Harbor, a worldwide gathering of renowned scientists and researchers whose work is leading the way to learn more about the health benefits of Wild Blueberries. Their findings are documented in a growing number of published studies on the potential health and disease-fighting benefits of Wild Blueberries. For news, recipes, and related health information about Wild Blueberries, visit http://www.wildblueberries.com. For the latest updates, read our blog. Visit us on Facebook or on Twitter.

Share article on social media or email:

RXNT and Appriss Health Partnership Enables Doctors to Connect Directly to State PDMPs


News Image

“We’re giving physicians a more powerful tool to safely prescribe controlled substances and help reduce the incidences of substance abuse.”

RXNT, a leader in healthcare technology solutions, in partnership with Appriss Health, is announcing a new feature that gives physicians direct access to state prescription drug monitoring programs (PDMPs). Healthcare providers using RXNT’s Electronic Health Records and Electronic Prescribing will be better equipped to identify and prevent substance abuse.

A PDMP is an electronic database for tracking controlled substance prescriptions in each state. They provide prescribers with timely and accurate information about patient behaviors and protect those at the highest risk. Every state (except Missouri) and the District of Columbia have a PDMP.

The alliance between RXNT and Appriss Health gives practitioners the ability to better monitor and manage controlled substance prescriptions 24/7 from anywhere. According to the U.S Centers for Disease Control and Prevention, nearly 70,000 Americans died from a drug overdose in 2019. Over 770,000 died in the 10-year period from 1999-2019.

“Our technology solutions are already one of the most user- and budget-friendly systems in the ambulatory care marketplace today. We’re excited to be able to combine Appriss’ leading-edge data analytics with our proven EHR and eRx solutions. We’re giving physicians a more powerful tool to safely prescribe controlled substances and help reduce the incidences of substance abuse,” said Randy Boldyga, RXNT President and CEO.

About RXNT

Since 1999, RXNT has provided award-winning, certified eRx, EHR, Practice Management, Medical Billing, and Full-Suite software to physician practices, healthcare providers, and billing companies. The company’s cost-effective, fully-integrated and cloud-based systems are designed to provide robust functionality while being easy to implement and use. For additional information, please visit http://www.rxnt.com.

For more information, please contact:

Tom Collinson

Executive Vice President, Business Development

410-777-8842

tcollinson@RXNT.com

Share article on social media or email:

Team Novo Nordisk and Beyond Type 1 Announce New Partnership


News Image

“This is one of the most symbiotic and natural partnerships in the history of the Team Novo Nordisk and we are eager to see what we can do together to change what it looks like to live with diabetes,” said Phil Southerland.

Team Novo Nordisk, the world’s first all-diabetes professional cycling team, and Beyond Type 1, a global nonprofit organization changing what it means to live with diabetes, announced a partnership that will bring the two organizations together around in-person events and online activations to inspire, educate and empower everyone affected by diabetes.

Beyond Type 1 is a nonprofit organization changing what it means to live with diabetes. By leveraging the power of social media and technology, Beyond Type 1 empowers people to both live well today and support a better tomorrow. Through peer support programs, global campaigns, and digital platforms, Beyond Type 1 is uniting the global diabetes community across both type 1 and type 2 diabetes, helping to change what it means to live with chronic illness.

“This is one of the most symbiotic and natural partnerships in the history of the Team Novo Nordisk and we are eager to see what we can do together to change what it looks like to live with diabetes,” said Team Novo Nordisk CEO and Co-Founder Phil Southerland. “We’ve enjoyed watching Beyond Type 1’s growth over the past five years and can’t wait to empower our combined communities to keep chasing their dreams with diabetes.”

Recently Beyond Type 1 announced that it would expand its collection of websites, resources, and unique content into five new languages: Dutch, French, German, Italian, and Swedish. This builds upon its existing English and Spanish content.

2020 marks Team Novo Nordisk’s eighth season racing as part of the International Cycling Union (UCI) ProSeries, which takes them to numerous countries around the world in Europe, USA, Africa, and Asia as they race to change diabetes. Team Novo Nordisk has more than three dozen athletes and ambassadors from 18 different countries within its pipeline. This includes six native French speakers, six native Spanish speakers, five native Dutch speakers, two native German speakers, and two native Italian speakers.

“Team Novo Nordisk’s international cyclists offer tremendous inspiration, showcasing how people with diabetes can compete at the highest of levels,” said Beyond Type 1 CEO Thom Scher. “We’re thrilled to be working together to serve new communities globally, working together to provide education and raise awareness for everyone impacted by diabetes.”

By combining the strengths and expertise of the two organizations, this partnership will focus on high-value and engaging digital content that empowers the global diabetes community.

About Team Novo Nordisk

Team Novo Nordisk is a global all-diabetes sports team of cyclists spearheaded by the world’s first all-diabetes professional cycling team. In 2012, Phil Southerland, co-founder and CEO of the team, and global healthcare company Novo Nordisk, came together to create Team Novo Nordisk, based on a shared vision to inspire, educate and empower people around the world affected by diabetes. For more information, go to http://www.teamnovonordisk.com.

About Beyond Type 1

Beyond Type 1 is a nonprofit organization changing what it means to live with diabetes. By leveraging the power of social media and technology, Beyond Type 1 empowers people to both live well today and support a better tomorrow. Through peer support programs, global campaigns, and digital platforms, Beyond Type 1 is uniting the global diabetes community across both type 1 and type 2 diabetes, helping to change what it means to live with chronic illness.

###

Media Contacts:

Fitzalan Crowe for Team Novo Nordisk

Fitzalan.crowe@teamnovonordisk.com

+1-703-596-2020

Dana Howe

Director of Brand Communications, Beyond Type 1

press@beyondtype1.org

Share article on social media or email:

HYLETE Announces Regulation A Offering


HYLETE

HYLETE, Inc., a fitness lifestyle brand built, backed, and driven by the HYLETE Nation community, has announced a $12 million equity raise under a Regulation A Tier 2 offering. HYLETE was founded in 2012 as a direct-to-consumer brand and has experienced significant growth, with 2019 net revenues of over $12.5 million.

Regulation A (Tier 2) is a securities offering that allows private companies to raise investment amounts of up to $50 million from the public. Reg A enables companies to offer shares to the general public and not just accredited investors.

HYLETE is offering up to 12 million shares of the company’s common stock that will be available to investors at $1.00 per share, with a minimum purchase of 500 shares per investor. The SEC has qualified this offering.

This equity offering will be HYLETE’s ninth crowdfunding round. Since 2015, HYLETE has gained more than 4,900 investors, of which, 85% are loyal customers who have infused $9.9 million into the company. This inspired the HYLETE-coined term, “investomer.”

“We originally designed and launched a patented cross-training short. Today, we now have an extensive line of men’s and women’s apparel, footwear, and gear,” said Ron L. Wilson II, CEO, and Co-founder. “We believe that our brand’s impact should live beyond the products that we sell, and as such, our energy is equally focused on inspiring the well-being of our community – a community that we call the HYLETE Nation.”

With a fully completed offering, HYLETE intends to apply for a direct listing on the Nasdaq Stock Exchange. Although the company intends to apply for quotation of its common stock on Nasdaq, there are a number of requirements that the company may or may not be able to satisfy in a timely manner. Even if the company obtains that quotation, it is unknown the extent to which investor interest will lead to the development and maintenance of a liquid trading market. Investors should assume that they may not be able to liquidate investments for some time or be able to pledge these shares as collateral.

About HYLETE

HYLETE has created a fitness lifestyle ecosystem that has been built, backed, and driven by its community. HYLETE aspires to not only build premium athletic wear, but also to engage and inspire its community with fitness apps, content, challenges and education.

About StartEngine

StartEngine is the leading equity crowdfunding platform in the U.S., where everyday people can find and invest in private companies. StartEngine has helped more than 325 companies raise $125M+ from a community of over 225,000 prospective investors. Based in Los Angeles, the company was created in 2014 by Howard Marks, co-founder of Activision, and Ron Miller.

StartEngine is committed to revolutionizing the ways companies raise capital through the JOBS Act and helping entrepreneurs achieve their dreams. StartEngine Crowdfunding Inc. is not a broker-dealer, funding portal or investment adviser. StartEngine Capital, LLC is a funding portal registered with the US Securities and Exchange Commission (SEC) and a member of the Financial Industry Regulatory Authority (FINRA). StartEngine Primary LLC is a broker-dealer registered with the SEC and FINRA/SIPC.

Share article on social media or email:

Curvo Labs Accelerates Launch of Lookup for Healthcare Supply Chain Amidst COVID-19 Pandemic


“Throughout my ten years of consulting, I watched many companies try to build a visualization utility, and none of them succeeded like Curvo has. Curvo took a traditional benchmarking tool and turned it on its head – and best of all, it is incredibly easy to use. I’m impressed!” – Paul Sas

Curvo Labs, Inc., an industry-leading technology platform for the healthcare supply chain, announced today the accelerated release of Lookup by Curvo, a new, unbiased clinical product research and market pricing solution built for hospital supply chain and value analysis professionals.

Lookup by Curvo provides holistic clinical product intelligence for the modern supply chain. Users can instantly search over 1.2 million unique products, view a device’s cost and safety information within a second, and use a dynamic price spray graph to visualize market competitiveness. The unbiased solution provides insight into over $22 billion in trailing twelve months clinical supply purchase data and gives hospital teams the information they need to engage in data-driven decisions with clinicians and suppliers. The ability to research product alternatives, prices and suppliers within Curvo’s data intelligence is what the company hopes will help hospitals in this critical time of need.

Curvo CEO Andy Perry says, “During this incredibly trying time, hospital supply chains are not merely dealing with product shortages of masks and personal protective equipment, but they also must contend with price gouging and suspicious sources. As a company, we have been working to best help our customers deal with the COVID-19 pandemic. We have decided to leverage our product development pipeline, our network and our data assets in any way we can. We have been excited about this product for a while, and we are happy to widen its free release to assist in a time of crisis.”

Paul Sas, Vice President of Supply Chain, Purchasing & Construction Management at Palomar Health, had this to say: “I have been absolutely blown away with the Lookup by Curvo solution. Throughout my ten years of consulting, I watched many companies try to build a visualization utility, and none of them succeeded like Curvo has. Curvo took a traditional benchmarking tool and turned it on its head – and best of all, it is incredibly easy to use. I’m impressed!”

Ben Peyronnin, Product Manager, explains it this way: “There is no other resource in the industry that brings this many points of data together while remaining this easy to use. Lookup by Curvo pulls data from FDA UDI, Device Recalls, MAUDE reports, Orthopedic Network News classifications and pairs them with market pricing details for unmatched transparency. And, with zero IT support or integration required, supply chain teams can benefit immediately.”

Today, Curvo is announcing free access to this new product from now until July 31st for any healthcare provider organization. Supply chain, value analysis, materials management, and procurement teams may use this powerful solution completely free of charge for a limited time to assist during COVID-19 supply chain challenges.

Sign up for access to Lookup by Curvo here for complimentary access through July 31st: curvolabs.com/lookup.

Suppliers of PPE or other clinical devices who are interested in making their product catalog available free of charge to users of the Lookup by Curvo utility may contact Ben Peyronnin at lookup@curvolabs.com.

About Curvo Labs

For clinical supply chain teams who don’t have access to the data in the way they need it, the people that can understand how to leverage the data, or the technologies to enable timely execution, Curvo Labs powers the partnership between clinicians & supply chain to optimize spend, maximize quality, & make a dent in the cost of healthcare. Curvo is a Software-as-a-Service company that provides supply chain teams at hospitals and health systems with trustworthy data, collaborative technology, and trackable savings.

Find out what Curvo can do for your organization today and visit curvolabs.com.

Share article on social media or email:

The Saga Of Red Dog” begins the fascinating story of Red’s canine life.


News Image

“Red: The Saga Of Red Dog”: a gripping tale that contains a profound purpose of inspiring the readers and dog lovers with Red’s true story of her difficulties in life. “Red: The Saga Of Red Dog” is the creation of published author R.C. Besteder, a retired lieutenant colonel. He served as senior pastor of six churches over the course of twenty-one years and was a chaplain in the USAF for twenty-one years as well.

Besteder shares, “Red, The Saga of Red Dog, is the first of two volumes on a redbone hound of wolf mix that became a ferial dog and one of her pups, ‘Rot.’ In this book and the second, two significant questions asked by dog lovers are answered. The first has to do with whether a dog has a soul and the second is whether a dog has an afterlife? Question one is answered in the first book and question two will be answered in the second. Red was a real dog but her story is presented in a fictional narrative. A principle is illustrated namely that the righteous care for their animals. As opposed to animal abuse, what happened to Red, is intended to enlighten readers on the proper way to treat one’s dog. There is mystery in the composition of Red. It’s left to the reader to pick up the many hints the author has in mind and in one special instance what appears to be a contradiction has a deeper meaning for the reader to comprehend. This book is quite educational and will contribute to the reader’s knowledge and appreciation of dogs. The background of the early life of Red is one in which the author was reared and is presented with great detail and accuracy. Note Red’s first Christmas. The raccoon hunt was an actual experience of the writer. Red born in Pennsylvania runs with wolves through New York and into Canada, and in her sojourn ends up in Florida. Red is fast moving and exciting. It was written with great emotion and it is hoped that you will be inwardly compelled to follow the good against evil plot to the completion of Rot, son of Red.”

Published by Christian Faith Publishing, R.C. Besteder’s new book is the stirring story of a dog and her life. Here, readers will find the answer to the question of whether a dog has a soul. Likewise, they will be illuminated with the proper way of treating dogs, which will greatly help to avoid cases of abuse.

View a synopsis of “Red: The Saga Of Red Dog” on YouTube.

Consumers can purchase “Red: The Saga Of Red Dog” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Red: The Saga Of Red Dog,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

Copeify Donates $5 Million of Wellness Subscriptions to High Schools and Colleges, Offering Remote Health and Support Solution to Millions of Young Adults


Copeify Conditions Students for Health and Life

“What started for us as a mission to improve student health and resilience on one campus, has grown as a national mandate to deliver our remote wellness platform to the 43 million young adults and students in America.” Drew Bartkiewicz, CEO Copeify

Patriapps, the veteran-led software developer today announces $5M worth of software donations of Copeify, the only self-care and life-skills application for high schools, colleges and universities. The machine learning application is geared for all young adults, and is designed to build personal health and resilience without the need for any personal information.

As a result of the announcement, Patriapps will make Copeify available to all high schools, colleges and universities for free until the next academic year, or beyond, as the need for remote wellness technology has reached a new high point with the Coronavirus pandemic.

Copeify has been developed for young adults and teachers to anonymously grow their knowledge and practice of nutrition, motivation, health and mindfulness. The AI-enhanced content and questions (modeled after the Army’s readiness, health and resilience programs) help young adults, students and faculty to help grow their life-skills and coping capabilities. The application creates better outcomes for young adults, like supporting paths to happiness and health, and reducing the frequency of depression, addiction and anxiety.

“As evidenced by the coronavirus, we are all reminded that complete wellness is not just the domain of one campus. Complete wellness for young adults is a continual, 24/7 condition and practice that can be learned by anyone, anywhere,” said Drew Bartkiewicz, CEO of Copeify and Army combat veteran who graduated from West Point. “What started for us as a mission to improve student health, readiness and resilience on one campus, has grown as a national mandate to deliver our remote wellness platform to the 43 million young adults and students in America.”

Copeify leverages the sciences of self-care and young adult development to gradually improve personal levels of happiness, health, kindness and resilience.

The global coronavirus has dramatically heightened the need for remote wellness platforms to be an essential part of all high school and college experiences. Copeify is the first to step into this void with a Software-as-a-Service (SaaS) model.

Without the need for any personally identifiable information, Copeify builds personal readiness and resilience with:

  • Smart notifications on the new aspects of coping and character, health and happiness.
  • Personalized articles and videos about healthy lifestyles, social skills and emotional intelligence.
  • Interactive CopeScores that gamify and offer tools to grow into a healthier and happier life.
  • Option for schools and colleges to use the platform for fundraising of wellness programs.

“Young people and those who teach them need to increase their coping capacities in a more regular and remote way, with complete privacy,” said Major General Malcolm Frost, U.S. Army Retired. “Copeify is an intelligent and anonymous platform for both young adults and faculty to discover complete wellness in the same medium, so they can thrive in an academic and social environments and better combat both the uncertainties of COVID-19 and life itself.

Copeify is now available as a software donation to high schools, colleges and universities, and the organizations that support them. Issuance of the software as a service will be done on a first come, first serve basis.

Copeify is an American-made subsidiary brand of Patriapps, which commits the $5M software pledge on behalf of all veterans and health care workers exemplifying readiness and resilience. The CEO of Copeify, Drew Bartkiewicz, was the creator of award winning apps like lettrs and the personalized health intelligence system, Reservoire Health. He is the Chairman and founder of Patriapps Impact Apps.

Media Contact:

Jen Basco

Phone: 860.751.4321

Email: jen@copeify.com

Share article on social media or email:

BullFrog AI Secures $200K from TEDCO’s Seed Fund


News Image

“We are thrilled to be working with TEDCO toward building the future of our company. Our mission is to find the link between therapies and patients and improve their lives,” said BullFrog AI’s Founder and CEO, Vin Singh.

BullFrog AI, Inc, a precision pharmaceutical company built around a powerful artificial intelligence (AI) platform, proudly announces TEDCO’s Seed Fund made its first investment of $200,000. TEDCO’s Seed Fund invests in and partners with early-stage companies. Through seed funding and start-up related services, TEDCO works with the entrepreneurs to ensure they have the tools they need for success.

“We are thrilled to be working with TEDCO toward building the future of our company. Our mission is to find the link between therapies and patients and improve their lives,” said BullFrog AI’s Founder and CEO, Vin Singh. “Using our proprietary technology platform, we aim to predict which patients will benefit from which medications, effectively improving clinical outcomes and eliminating the problem of trial-and-error prescriptions.”

BullFrog AI uses a proprietary artificial intelligence platform called bfLEAPTM that enables biopharmaceutical companies to be more successful in their clinical development programs. The Seed Fund money will contribute to additional development work with John Hopkins University Applied Physics Laboratory not-for-profit research center. The funds will also support commercial activities to create partnerships with biopharmaceutical companies for clinical development projects.

“BullFrog AI’s precision pharmaceutical platform has the potential to make a huge impact on next generation clinical development programs,” said Frank Glover, Lead Director, TEDCO Seed & Director, MVF. “Vin Singh is an experienced entrepreneur and TEDCO is excited to be partnered with Vin and BullFrog.”

For more information on BullFrog AI, visit http://www.bullfrogai.com.

About BullFrog AI

BullFrog AI is an innovator in artificial intelligence. Its proprietary bfLEAPTM analytics engine is the only tool of its kind, designed to analyze massive, complex, multi-factorial clinical data sets. BullFrog AI’s technology is poised to revolutionize drug development, enabling researchers and clinicians to match therapies to patients, streamlining clinical trials, reducing development costs and accelerating R&D cycle time to drug approval and commercial launch. BullFrog AI has an exceptional team of life science industry leaders, AI technologists, scientists, physicians and advisors, all determined to make BullFrog AI become the undisputed leader in precision medicine.

About TEDCO

TEDCO provides resources and connections that early-stage technology and life sciences companies need to thrive in Maryland. TEDCO’s mission is to discover, invest in, and help build great Maryland-based companies. Learn more at http://www.tedcomd.com.

For more information regarding BullFrog AI, contact:

Vin Singh, Founder and CEO

Vin@Bullfrogai.com

301-367-2055

http://www.BullFrogAI.com

For Media Inquiries, please contact:

Liz Thibodeau, Thibodeau Media Group

Liz@thibmedia.com

http://www.ThibMedia.com

Share article on social media or email:

NeoTract Designates Dr. Jeffrey Stern as UroLift® Center of Excellence


News Image

“This designation recognizes Dr. Jeffrey Stern as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Jeffrey Stern, M.D., Academic Urology in Sun City West, AZ has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Stern has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“This designation recognizes Dr. Jeffrey Stern as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “We are pleased to see the continued acceptance of the UroLift System as a standard of care treatment that may allow men to discontinue the use of BPH medications and improve their quality of life.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504 nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email: